Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Cardiology · Hereditary transthyretin amyloidosis

Managing hATTR: Treatment Options and Strategies

At a Glance

Hereditary ATTR amyloidosis can be treated with medicines that either stabilize the transthyretin protein or reduce its production. The best choice depends on heart or nerve involvement, mutation, safety risks, and the monitoring you can manage.

Modern treatment for hATTR has shifted from managing symptoms to targeting the underlying cause of the disease. There are now two primary ways to intervene: stabilizing the protein so it is less likely to fall apart, or silencing the production of the protein [1][2].

TTR Stabilizers: Keeping the Protein Whole

Stabilizers act like a “lock” that holds the four-part TTR protein (the tetramer) together. If the protein stays together, it is much less likely to misfold into the amyloid fibers that damage your heart and nerves [P-077].

  • Tafamidis and Acoramidis: These medications are approved in various jurisdictions for ATTR cardiomyopathy (heart involvement) [1]. In long-term studies, they have been shown to reduce the risk of death and heart-related hospitalizations while helping patients maintain their physical strength and quality of life [3][4].
  • Diflunisal: This is an older non-steroidal anti-inflammatory drug (NSAID) that is sometimes used “off-label” to stabilize TTR [P-076]. It carries significant risks. Diflunisal can worsen fluid retention and heart failure, and can cause renal injury, gastrointestinal bleeding, and blood-pressure problems. You should absolutely not start or stop it without the guidance of your amyloidosis team [P-076].

TTR Silencers: Reducing Production at the Source

Silencers use advanced technology (called RNA interference or antisense oligonucleotides) to tell your liver to substantially reduce its production of the TTR protein [P-071]. By lowering the amount of TTR in your blood, these drugs reduce the likelihood of further amyloid deposition and can slow progression, though they do not reliably reverse established organ damage [P-085].

Medication Method Focus / Evidence Common Risks/Notes
Patisiran IV Infusion (every 3 weeks) Approved for Nerves (Polyneuropathy) Requires premedication (steroids/antihistamines) to prevent infusion reactions [5].
Vutrisiran Injection (every 3 months) Nerves (Polyneuropathy); Cardiac indications approved or under review in various jurisdictions. Generally well-tolerated; may cause mild skin reactions at the injection site [6].
Inotersen Injection (weekly) Approved for Nerves (Polyneuropathy) Requires strict monitoring for low platelets and kidney inflammation [7].
Eplontersen Injection (monthly) Approved for Nerves (Polyneuropathy); Investigational heart data. Designed for self-administration; shows strong TTR reduction [8].

Critical Safety and Monitoring

Because silencers are powerful, they require specific safety precautions:

  1. Monitoring Inotersen: This drug can cause a sudden drop in platelets (the cells that help your blood clot) or cause inflammation in the kidneys (glomerulonephritis) [7]. If you are on this medication, you will need frequent blood and urine tests to catch these issues before they become serious [9].
  2. Vitamin A Supplementation: TTR is the primary transporter of the complex that carries Vitamin A in your blood. Because silencers lower TTR levels, they also lower your Vitamin A levels [P-075]. Most patients on a silencer must take a specific daily Vitamin A supplement. You should stick strictly to the prescribed amount (typically the recommended daily allowance) because excess vitamin A can be toxic. Obtain prompt ophthalmologic assessment for night-vision or other visual changes [10][11].

Supportive Symptom Management

Disease-modifying treatments do not replace the need for supportive care to address existing organ complications. Your care team will actively manage everyday issues: careful diuresis and rhythm management for cardiac disease, treatment of orthostatic hypotension and gastrointestinal dysfunction, physical and occupational therapy, and neuropathic-pain care. Do not independently change your heart or blood-pressure medications.

The Selective Role of Liver Transplantation

Historically, a liver transplant was used as a primary strategy because the liver produces most of the TTR protein. However, this is used much less often today. A liver transplant does not eliminate extrahepatic TTR production; the brain (choroid plexus) and the eyes also produce TTR, meaning patients can still develop “leptomeningeal” amyloid (brain amyloid) years after the transplant [12][13]. Furthermore, wild-type TTR from the new liver can continue to deposit on existing amyloid in the heart, causing disease progression [14]. Modern stabilizers and silencers are now often preferred because they avoid the risks of major surgery and long-term anti-rejection medications [15][16].

Common questions in this guide

What are the main treatment options for hereditary ATTR amyloidosis?
The two main disease-modifying approaches are TTR stabilizers and TTR silencers. Stabilizers help keep the transthyretin protein intact, while silencers reduce how much of the protein the liver makes. Your heart or nerve involvement, genetic variant, other health conditions, and monitoring needs help guide the choice.
Which hATTR medicines are used for heart involvement?
Tafamidis and acoramidis are approved for ATTR cardiomyopathy in various jurisdictions and can reduce the risk of death and heart-related hospitalizations. Vutrisiran has cardiac indications approved or under review in various jurisdictions, while eplontersen has investigational heart data. Approval and availability depend on where you live and your clinical situation.
What should I know before taking a TTR silencer?
TTR silencers can slow further amyloid buildup but do not reliably reverse organ damage that is already present. They also lower vitamin A levels, so most patients need a prescribed vitamin A supplement and should report night-vision or other visual changes promptly. Do not increase the supplement without medical advice.
What monitoring is needed with inotersen?
Inotersen can cause a dangerous drop in platelets or inflammation in the kidneys. People taking it need regular blood and urine tests so their care team can identify these problems early. Tell the team about any history of low platelets or kidney disease before treatment.
Why do TTR silencers require vitamin A?
Transthyretin normally helps carry vitamin A in the blood. When a silencer lowers transthyretin, vitamin A levels can also fall, so most people taking a silencer need a prescribed daily supplement. Take only the recommended amount and seek prompt eye care for night-vision problems or other visual changes.
Is liver transplant still used to treat hATTR?
Liver transplantation is used much less often than in the past because medicines can stabilize transthyretin or reduce its production without major surgery. A transplant does not stop transthyretin made in the brain and eyes, and protein from the new liver can still add to existing heart deposits. Whether it has a role depends on the individual case and specialist evaluation.
Can I take diflunisal or change my hATTR medicine on my own?
Diflunisal is an older anti-inflammatory drug sometimes used off-label to stabilize transthyretin, but it can worsen fluid retention and heart failure and injure the kidneys or digestive tract. Do not start, stop, or change diflunisal or other heart and blood-pressure medicines without guidance from your amyloidosis team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and mutation, am I a better candidate for a 'stabilizer' or a 'silencer'?
  2. 2.If we choose inotersen, how will we coordinate the frequent blood and urine tests required to monitor my platelets and kidneys?
  3. 3.What specific Vitamin A supplement dose do you recommend while I am on a silencer, and are there signs of deficiency I should watch for?
  4. 4.Since I have heart involvement, what is the latest evidence for using vutrisiran or eplontersen compared to tafamidis?
  5. 5.Are there any clinical trials available that combine a stabilizer and a silencer, and would that be appropriate for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.

    Benbrahim M, Norman K, Sanchorawala V, et al.

    Journal of cardiovascular pharmacology 2021; (77(5)):544-548 doi:10.1097/FJC.0000000000001004.

    PMID: 33657048
  2. 2

    Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.

    Alcantara M, Mezei MM, Baker SK, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2022; (49(1)):7-18 doi:10.1017/cjn.2021.34.

    PMID: 33631091
  3. 3

    Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.

    Lamb YN

    American journal of cardiovascular drugs : drugs, devices, and other interventions 2021; (21(1)):113-121 doi:10.1007/s40256-020-00461-7.

    PMID: 33469827
  4. 4

    Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.

    Rapezzi C, Elliott P, Damy T, et al.

    JACC. Heart failure 2021; (9(2)):115-123 doi:10.1016/j.jchf.2020.09.011.

    PMID: 33309574
  5. 5

    Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

    Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.

    The New England journal of medicine 2018; (379(1)):11-21 doi:10.1056/NEJMoa1716153.

    PMID: 29972753
  6. 6

    Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B.

    Witteles RM, Garcia-Pavia P, Morbach C, et al.

    JACC. Advances 2025; (4(9)):102066 doi:10.1016/j.jacadv.2025.102066.

    PMID: 40848527
  7. 7

    Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

    Benson MD, Waddington-Cruz M, Berk JL, et al.

    The New England journal of medicine 2018; (379(1)):22-31 doi:10.1056/NEJMoa1716793.

    PMID: 29972757
  8. 8

    Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

    Conceição I, Berk JL, Weiler M, et al.

    Journal of neurology 2024; (271(10)):6655-6666 doi:10.1007/s00415-024-12616-6.

    PMID: 39138650
  9. 9

    Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

    Gertz MA, Scheinberg M, Waddington-Cruz M, et al.

    Expert review of clinical pharmacology 2019; (12(8)):701-711 doi:10.1080/17512433.2019.1635008.

    PMID: 31268366
  10. 10

    Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

    Nie T, Heo YA, Shirley M

    Drugs 2023; (83(15)):1425-1432 doi:10.1007/s40265-023-01943-z.

    PMID: 37728865
  11. 11

    Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.

    Ioannou A, Fontana M, Gillmore JD

    Heart international 2023; (17(1)):27-35 doi:10.17925/HI.2023.17.1.27.

    PMID: 37456349
  12. 12

    Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis.

    Sekijima Y, Sousa L

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(2)):117-128 doi:10.1080/13506129.2024.2435573.

    PMID: 39627935
  13. 13

    Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis.

    Sekijima Y, Yazaki M, Oguchi K, et al.

    Neurology 2016; (87(8)):773-81 doi:10.1212/WNL.0000000000003001.

    PMID: 27466465
  14. 14

    Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

    Saelices L, Chung K, Lee JH, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2018; (115(29)):E6741-E6750 doi:10.1073/pnas.1805131115.

    PMID: 29954863
  15. 15

    Amyloidogenic phenotypical variation affects post-transplant outcome of hereditary transthyretin amyloidosis: a retrospective study.

    Wilczek HE, Tranäng M, Coelho T, Ericzon BG

    eGastroenterology 2026; (4(1)):e100243 doi:10.1136/egastro-2025-100243.

    PMID: 41659301
  16. 16

    Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis.

    Ando Y, Adams D, Benson MD, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(3)):143-155 doi:10.1080/13506129.2022.2052838.

    PMID: 35652823

This page is for informational purposes only and does not constitute medical advice. Discuss hATTR medicines, vitamin A supplementation, monitoring, and transplant decisions with your amyloidosis team.

Get notified when new evidence is published on Hereditary ATTR amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.